Mom's Story, A Child Learns About MS

Available on Amazon and www.marynickum.com

Thursday, December 1, 2011

Positive Results Announced from Second Phase III Study of Alemtuzumab in MS

Genzyme has announced that the experimental intravenous therapy alemtuzumab (with a proposed brand name Lemtrada™) met two primary endpoints by significantly reducing relapse rates and the worsening of disability in a two-year study comparing alemtuzumab to standard subcutaneous dosing of Rebif® (interferon beta-1a, EMD Serono Inc. and Pfizer). The study, called CARE-MS II, involved 840 people with relapsing-remitting MS. The results were announced in a November 14, 2011 press release, which also indicated that the company plans to apply in early 2012 to the U.S. Food and Drug Administration for marketing approval. Data analysis is ongoing and the company expects to provide a full report at an upcoming medical meeting. Alemtuzumab has been designated by the FDA as a “Fast Track Product,” which should expedite its future review.

Amazon Search Sidebar Gadget

Book Marketing

Goodreads

About Me

Mary J. Nickum is a retired librarian, who is now an editor and freelance writer of fish culture related articles. Her primary focus is on science for the public. She has chosen to extend her science for the public outreach to children.